Skip to content

Michael H. Baumann

National Institute on Drug Abuse, National Institutes of Health

56 papers in the library · 2,809 citations · publishing 1995-2026

Papers

Sort Most recent Most cited

Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine.

Annals of the New York Academy of Sciences September 1, 2000 Michael H. Baumann, John Pablo, S F Ali et al. 37 citations

Ibogaine (IBO) is a plant-derived alkaloid that is being evaluated as a possible medication for substance use disorders. When administered peripherally to monkeys and humans, IBO is rapidly converted to an o-demethylated metabolite, 12-hydroxyibogamine (NORIBO). We have found in rats that peak blood levels of NORIBO can exceed those of the parent compound, and NORIBO persists in the bloodstream...

DOI: 10.1111/j.1749-6632.2000.tb05210.x (opens in new tab) Full text (opens in new tab) Noribogaine Ibogaine metabolite Anti-addiction drug metabolite Addiction treatment +5

Comparative neurobiological effects of ibogaine and MK-801 in rats.

Drug and Alcohol Dependence May 1, 2000 Michael H. Baumann, Richard B Rothman, S F Ali 15 citations

Ibogaine is a plant-derived alkaloid with putative 'anti-addictive' properties. Although ibogaine binds to multiple targets in the brain, recent evidence suggests the drug acts as an N-methyl-D-aspartate (NMDA) antagonist similar to MK-801. The purpose of the present study was to compare neurochemical and neuroendocrine effects of ibogaine and MK-801 in vivo. Male rats received either i.p....

DOI: 10.1016/s0376-8716(99)00113-1 (opens in new tab) Full text (opens in new tab) Ibogaine Plant compound Anti-addiction compound Therapeutic compound +13

Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin

Synapse 2000 Richard B Rothman, Michael H. Baumann, Christina M Dersch et al. 933 citations

A large body of evidence supports the hypothesis that mesolimbic dopamine (DA) mediates, in animal models, the reinforcing effects of central nervous system stimulants such as cocaine and amphetamine. The role DA plays in mediating amphetamine-type subjective effects of stimulants in humans remains to be established. Both amphetamine and cocaine increase norepinephrine (NE) via stimulation of...

Neurochemical and Neuroendocrine Effects of Ibogaine in Rats: Comparison to MK-801.

Annals of the New York Academy of Sciences May 1, 1998 Michael H. Baumann, Richard B Rothman, Syed F. Ali 11 citations

Ibogaine (IBO) is a naturally-occurring indole compound that is being evaluated as a potential medication for substance use disorders. Although the precise mechanism of IBO action is unclear, recent in vitro data show this drug displays properties similar to the noncompetitive N-methyl-d-aspartate (NMDA) antagonist MK-801. The purpose of the present work was to compare In Vivo neurobiological...

DOI: 10.1111/j.1749-6632.1998.tb08240.x (opens in new tab) Full text (opens in new tab) Ibogaine: natural compound Ibogaine's effects Its action Mechanism +9

Neuroendocrine and neurochemical effects of acute ibogaine administration: a time course evaluation.

Brain Research October 21, 1996 S F Ali, Glenn D. Newport, William Slikker et al. 29 citations

Ibogaine (IBO) is an indole alkaloid that is reported to facilitate drug abstinence in substance abusers. Despite considerable investigation, the mechanism of IBO action in vivo and its suitability as a treatment for drug addiction remains unclear. The present study was designed to evaluate the time-course effects of acute IBO on neuroendocrine and neurochemical indices. Adult male rats were...

Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin.

Life Sciences 1995 Deborah C. Mash, J K Staley, Michael H. Baumann et al. 108 citations

Ibogaine is a hallucinogenic indole with putative efficacy for the treatment of cocaine, stimulant and opiate abuse. The purported efficacy of ibogaine following single dose administrations has led to the suggestion that a long-acting metabolite of ibogaine may explain in part how the drug reduces craving for psychostimulants and opiates. We report here that 12-hydroxyibogamine, a primary...